HRP20040107B1 - Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments - Google Patents

Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Info

Publication number
HRP20040107B1
HRP20040107B1 HR20040107A HRP20040107A HRP20040107B1 HR P20040107 B1 HRP20040107 B1 HR P20040107B1 HR 20040107 A HR20040107 A HR 20040107A HR P20040107 A HRP20040107 A HR P20040107A HR P20040107 B1 HRP20040107 B1 HR P20040107B1
Authority
HR
Croatia
Prior art keywords
flibanserin
preparation
technical process
preparing medicaments
stable polymorph
Prior art date
Application number
HR20040107A
Other languages
English (en)
Croatian (hr)
Inventor
Bombarda Carlo
Dubini Enrica
Ezhaya Antoine
Schneider Heinrich
Original Assignee
Bidachem S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem S.P.A. filed Critical Bidachem S.P.A.
Publication of HRP20040107A2 publication Critical patent/HRP20040107A2/hr
Publication of HRP20040107B1 publication Critical patent/HRP20040107B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20040107A 2001-08-02 2004-01-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments HRP20040107B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (2)

Publication Number Publication Date
HRP20040107A2 HRP20040107A2 (en) 2004-06-30
HRP20040107B1 true HRP20040107B1 (en) 2012-02-29

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040107A HRP20040107B1 (en) 2001-08-02 2004-01-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Country Status (27)

Country Link
EP (2) EP1414816B1 (xx)
JP (1) JP3822601B2 (xx)
KR (1) KR100899297B1 (xx)
CN (1) CN1288147C (xx)
AR (2) AR036208A1 (xx)
AT (1) ATE288911T1 (xx)
AU (1) AU2002331361B2 (xx)
BR (1) BR0211601A (xx)
CA (1) CA2450093C (xx)
CO (1) CO5560572A2 (xx)
DE (1) DE60202958T2 (xx)
DK (1) DK1414816T3 (xx)
EA (1) EA006400B1 (xx)
ES (1) ES2237694T3 (xx)
HK (1) HK1070063A1 (xx)
HR (1) HRP20040107B1 (xx)
HU (1) HU228666B1 (xx)
IL (2) IL159151A0 (xx)
MX (1) MXPA04000913A (xx)
MY (1) MY127294A (xx)
NZ (1) NZ530510A (xx)
PL (1) PL210224B1 (xx)
PT (1) PT1414816E (xx)
RS (1) RS50742B (xx)
SI (1) SI1414816T1 (xx)
UA (1) UA76767C2 (xx)
WO (1) WO2003014079A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
WO2003097058A1 (en) * 2002-05-22 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions containing flibanserin polymorph a
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
NZ573382A (en) * 2006-05-09 2012-02-24 Boehringer Ingelheim Int Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2054041A2 (en) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
EP2097389B1 (en) 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Also Published As

Publication number Publication date
NZ530510A (en) 2004-07-30
AR077416A2 (es) 2011-08-24
IL159151A0 (en) 2004-06-01
YU7804A (sh) 2006-08-17
MXPA04000913A (es) 2004-10-27
ATE288911T1 (de) 2005-02-15
EP1518858A1 (en) 2005-03-30
KR20040023704A (ko) 2004-03-18
DE60202958T2 (de) 2006-04-06
HUP0401201A3 (en) 2004-11-29
EA006400B1 (ru) 2005-12-29
CA2450093C (en) 2008-09-23
EP1414816A1 (en) 2004-05-06
WO2003014079A1 (en) 2003-02-20
IL159151A (en) 2009-09-22
BR0211601A (pt) 2004-08-24
PT1414816E (pt) 2005-04-29
DK1414816T3 (da) 2005-04-11
WO2003014079A8 (en) 2003-11-20
RS50742B (sr) 2010-08-31
DE60202958D1 (de) 2005-03-17
HU228666B1 (en) 2013-05-28
MY127294A (en) 2006-11-30
EP1414816B1 (en) 2005-02-09
JP3822601B2 (ja) 2006-09-20
JP2004537597A (ja) 2004-12-16
EA200400252A1 (ru) 2004-08-26
CA2450093A1 (en) 2003-02-20
AR036208A1 (es) 2004-08-18
PL210224B1 (pl) 2011-12-30
CO5560572A2 (es) 2005-09-30
HK1070063A1 (en) 2005-06-10
SI1414816T1 (en) 2005-06-30
CN1551879A (zh) 2004-12-01
CN1288147C (zh) 2006-12-06
HRP20040107A2 (en) 2004-06-30
KR100899297B1 (ko) 2009-05-26
ES2237694T3 (es) 2005-08-01
HUP0401201A2 (hu) 2004-10-28
AU2002331361B2 (en) 2008-06-05
PL364598A1 (en) 2004-12-13
UA76767C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
HRP20040107B1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
HUP0402191A3 (en) Acetylene derivatives having human matabotropic glutamate receptor antagonistic activity, process for producing them, pharmaceutical compositions containing them and use thereof
NO20031694L (no) Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
SE0100901D0 (sv) New composition
IL153011A0 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
SE9904505D0 (sv) Novel compounds
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
HRP20030154B1 (en) Preparation of risperidone
PT1506185E (pt) Compostos novos e sua utilizacao
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
IL150528A0 (en) Ibuprofen containing active agent preparation
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
FR2848851B1 (fr) Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
NO20040912L (no) Beskyttede 3,5-dihydroksy-2,2-dimetyl-valeroamider for syntese av epotiloner og derivater derav, og fremgangsmate for fremstilling og andvendelse derav.
SE9803280D0 (sv) Novel compounds
MXPA03003466A (es) Derivados de piranosido.
NO20040403L (no) Stabil polymorf av flibanserin, teknisk fremgangsmåte for fremstilling derav og anvendelse derav for fremstlling av medikamenter
TWI346113B (en) Stable polymorph of flibanserin, technical process for its preparation and use thereof for preparing medicaments
ZA200207523B (en) Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140702

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20150730